To include your compound in the COVID-19 Resource Center, submit it here.

Sage's brexanolone meets in Phase III trials for PPD

Sage Therapeutics Inc. (NASDAQ:SAGE) said brexanolone (formerly SAGE-547) met the primary endpoint in a pair of Phase III trials in the Hummingbird program to treat postpartum depression (PPD). Next year, the company plans to submit an NDA to

Read the full 383 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE